• 1
    Scharschmidt BF. Bile formation and cholestasis. In: ZakimD, BoyerTD, eds. Hepatology: A Textbook of Liver Disease. Philadelphia: W.B. Saunders, 1990: 303304.
  • 2
    Kaplan MM. Primary biliary cirrhosis. N Engl J Med 1996; 335: 15701580.
  • 3
    Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 1991; 324: 15481554.
  • 4
    Gershwin ME, Ansari AA, Mackay IR, Nakanuma Y, Nishio A, Rowley MJ, Coppel RL. Primary biliary cirrhosis: an orchestrated immune response against epithelial cells. Immunol Rev 2000; 174: 210225.
  • 5
    Sokol RJ, Winklhofer-Roob BM, Devereaux MW, McKim JM Jr. Generation of hydroperoxides in isolated rat hepatocytes and hepatic mitochondria exposed to hydrophobic bile acids. Gastroenterology 1995; 109: 12491256.
  • 6
    Galle PR, Theilmann L, Raedsch R, Otto G, Stiehl A. Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes. HEPATOLOGY 1990; 12: 486491.
  • 7
    Scheuer PJ. Liver Biopsy Interpretation. 3rd ed. London: Balliere Tindall, 1980: 3659.
  • 8
    Ratan RR, Murphy TH, Baraban JM. Oxidative stress induces apoptosis in embryonic cortical neurons. J Neurochem 1994; 62: 376379.
  • 9
    Verhaegen S, McGowan AJ, Brophy AR, Fernandes RS, Cotter TG. Inhibition of apoptosis by antioxidants in the human HL-60 leukemia cell line. Biochem Pharmacol 1995; 50: 10211029.
  • 10
    Rodrigues CM, Fan G, Ma X, Kren BT, Steer CJ. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 1998; 101: 27902799.
  • 11
    Rodrigues CM, Fan G, Wong PY, Kren BT, Steer CJ. Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production. Mol Med 1998; 4: 165178.
  • 12
    Sokol RJ, McKim JM Jr., Goff MC, Ruyle SZ, Devereaux MW, Han D, Packer L, et al. Vitamin E reduces oxidant injury to mitochondria and the hepatotoxicity of taurochenodeoxycholic acid in the rat. Gastroenterology 1998; 114: 164174.
  • 13
    Sokol RJ, Devereaux MW, Khandwala R. Effect of oxypurinol, a xanthine oxidase inhibitor, on hepatic injury in the bile duct-ligated rat. Pediatr Res 1998; 44: 397401.
  • 14
    Tsai LY, Lee KT, Liu TZ. Evidence for accelerated generation of hydroxyl radicals in experimental obstructive jaundice of rats. Free Radic Biol Med 1998; 24: 732737.
  • 15
    Krahenbuhl S, Talos C, Fischer S, Reichen J. Toxicity of bile acids on the electron transport chain of isolated rat liver mitochondria. HEPATOLOGY 1994; 19: 471479.
  • 16
    Bernardi P. The permeability transition pore. Control points of a cyclosporin A-sensitive mitochondrial channel involved in cell death. Biochim Biophys Acta 1996; 1275: 59.
  • 17
    Botla R, Spivey JR, Aguilar H, Bronk SF, Gores GJ. Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection. J Pharmacol Exp Ther 1995; 272: 930938.
  • 18
    Yerushalmi B, Dahl R, Devereaux MW, Gumpricht E, Sokol RJ. Bile acid-induced rat hepatocyte apoptosis is inhibited by antioxidants and blockers of the mitochondrial permeability transition. HEPATOLOGY 2001; 33: 616626.
  • 19
    Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’. J Hepatol 2001; 35: 134146.
  • 20
    Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113: 884890.
  • 21
    Guldutuna S, Zimmer G, Imhof M, Bhatti S, You T, Leuschner U. Molecular aspects of membrane stabilization by ursodeoxycholate. Gastroenterology 1993; 104: 17361744.
  • 22
    Beuers U, Bilzer M, Chittattu A, Kullak-Ublick GA, Keppler D, Paumgartner G, Dombrowski F. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver. HEPATOLOGY 2001; 33: 12061216.
  • 23
    Qiao L, Yacoub A, Studer E, Gupta S, Pei XY, Grant S, Hylemon PB, et al. Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes. HEPATOLOGY 2002; 35: 779789.
  • 24
    Mitsuyoshi H, Nakashima T, Sumida Y, Yoh T, Nakajima Y, Ishikawa H, Inaba K. Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants. Biochem Biophys Res Commun 1999; 263: 537542.
  • 25
    Rodriguez-Ortigosa CM, Cincu RN, Sanz S, Ruiz F, Quiroga J, Prieto J. Effect of ursodeoxycholic acid on methionine adenosyltransferase activity and hepatic glutathione metabolism in rats. Gut 2002; 50: 701706.
  • 26
    National Research Council. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academies Press, 1997.
  • 27
    Kountouras J, Billing BH, Scheuer PJ. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol 1984; 65: 305311.
  • 28
    Miñana JB, Gomez-Cambronero L, Lloret A, Pallardo FV, Del Olmo J, Escudero A, Rodrigo JM. Mitochondrial oxidative stress and CD95 ligand: a dual mechanism for hepatocyte apoptosis in chronic alcoholism. HEPATOLOGY 2002; 35: 12051214.
  • 29
    Barja G. Measurement of mitochondrial oxygen radical production. In: YuBP, ed. Methods in Aging Research. Boca Raton: CRC Press, 1999: 533548.
  • 30
    Romero F, Viña J. A simple procedure to prepare isolated hepatocytes. Biochem Educ 1983; 11: 135136.
  • 31
    Juan G, Cavazzoni M, Saez GT, O'Connor JE. A fast kinetic method for assessing mitochondrial membrane potential in isolated hepatocytes with rhodamine 123 and flow cytometry. Cytometry 1994; 15: 335342.
  • 32
    Petit PX, O'Connor JE, Grunwald D, Brown SC. Analysis of the membrane potential of rat- and mouse-liver mitochondria by flow cytometry and possible applications. Eur J Biochem 1990; 194: 389397.
  • 33
    Maftah A, Petit JM, Ratinaud MH, Julien R. 10-N nonyl-acridine orange: a fluorescent probe which stains mitochondria independently of their energetic state. Biochem Biophys Res Commun 1989; 164: 185190.
  • 34
    Viña J, Hems R, Krebs HA. Reaction of formiminoglutamate with liver glutamate dehydrogenase. Biochem J 1978; 170: 711713.
  • 35
    Lu SC, Kuhlenkamp J, Garcia-Ruiz C, Kaplowitz N. Hormone-mediated down-regulation of hepatic glutathione synthesis in the rat. J Clin Invest 1991; 88: 260269.
  • 36
    Tateishi N, Higashi T, Shinya S, Naruse A, Sakamoto Y. Studies on the regulation of glutathione level in rat liver. J Biochem (Tokyo) 1974; 75: 93103.
  • 37
    Halestrap AP, Woodfield KY, Connern CP. Oxidative stress, thiol reagents, and membrane potential modulate the mitochondrial permeability transition by affecting nucleotide binding to the adenine nucleotide translocase. J Biol Chem 1997; 272: 33463354.
  • 38
    Paradies G, Petrosillo G, Pistolese M, Ruggiero FM. Reactive oxygen species affect mitochondrial electron transport complex I activity through oxidative cardiolipin damage. Gene 2002; 286: 135141.
  • 39
    Singh S, Shackleton G, Ah-Sing E, Chakraborty J, Bailey ME. Antioxidant defenses in the bile duct-ligated rat. Gastroenterology 1992; 103: 16251629.
  • 40
    Krahenbuhl S, Talos C, Lauterburg BH, Reichen J. Reduced antioxidative capacity in liver mitochondria from bile duct ligated rats. HEPATOLOGY 1995; 22: 607612.
  • 41
    Muriel P, Suarez OR, Gonzalez P, Zuniga L. Protective effect of S-adenosyl-L-methionine on liver damage induced by biliary obstruction in rats: a histological, ultrastructural and biochemical approach. J Hepatol 1994; 21: 95102.
  • 42
    Horowitz JH, Rypins EB, Henderson JM, Heymsfield SB, Moffitt SD, Bain RP, Chawla RK. Evidence for impairment of transsulfuration pathway in cirrhosis. Gastroenterology 1981; 81: 668675.
  • 43
    Look MP, Gerard A, Rao GS, Sudhop T, Fischer HP, Sauerbruch T, Spengler U. Interferon/antioxidant combination therapy for chronic hepatitis C—a controlled pilot trial. Antiviral Res 1999; 43: 113122.
  • 44
    Avila MA, Berasain C, Torres L, Martin-Duce A, Corrales FJ, Yang H, Prieto J. Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. J Hepatol 2000; 33: 907914.
  • 45
    Chavez E, Moreno-Sanchez R, Torres-Marquez ME, Zazueta C, Bravo C, Rodriquez-Enriquez S, Garcia C. Modulation of matrix Ca2+ content by the ADP/ATP carrier in brown adipose tissue mitochondria. Influence of membrane lipid composition. J Bioenerg Biomembr 1996; 28: 6976.
  • 46
    Lieser MJ, Park J, Natori S, Jones BA, Bronk SF, Gores GJ. Cholestasis confers resistance to the rat liver mitochondrial permeability transition. Gastroenterology 1998; 115: 693701.
  • 47
    Esteve JM, Mompo J, Garcia de Asunción, Sastre J, Asensi M, Boix J, Viña JR. Oxidative damage to mitochondrial DNA and glutathione oxidation in apoptosis: studies in vivo and in vitro. FASEB J 1999; 13: 10551064.
  • 48
    Corpechot C, Carrat F, Bonnad AM, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. HEPATOLOGY 2000; 32: 11961199.